128 related articles for article (PubMed ID: 20611009)
1. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
Pregun I; Gergics P; Dabasi G; Igaz P; Racz K; Tulassay Z
Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):386-7. PubMed ID: 20611009
[No Abstract] [Full Text] [Related]
2. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
Pregun I; Gergics P; Dabasi G; Igaz P; Racz K; Tulassay Z
Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):476-7. PubMed ID: 19382304
[No Abstract] [Full Text] [Related]
3. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).
Hillman N; Herranz L; Alvarez C; Martínez Olmos MA; Márco A; Gómez-Pan A
Exp Clin Endocrinol Diabetes; 1998; 106(3):226-30. PubMed ID: 9710364
[TBL] [Abstract][Full Text] [Related]
5. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis.
Massironi S; Zilli A; Fanetti I; Ciafardini C; Conte D; Peracchi M
Dig Liver Dis; 2015 Nov; 47(11):978-83. PubMed ID: 26321479
[TBL] [Abstract][Full Text] [Related]
6. [Development of silent gastric carcinoid in a type 1 diabetic patient with primer hypothyreosis].
Somogyi A; Ruzicska E; Varga T; Rácz K; Nagy G
Orv Hetil; 2007 Sep; 148(35):1667-71. PubMed ID: 17720674
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis of ileal carcinoid with contrast enhanced ultrasonic diagnosis].
Rickes S; Uhle C; Neye H; Ensberg D; Rauh P
Med Klin (Munich); 2009 Jul; 104(7):564-6. PubMed ID: 19618143
[No Abstract] [Full Text] [Related]
8. Treatment of type II gastric carcinoid tumors with somatostatin analogues.
Tomassetti P; Migliori M; Caletti GC; Fusaroli P; Corinaldesi R; Gullo L
N Engl J Med; 2000 Aug; 343(8):551-4. PubMed ID: 10954763
[No Abstract] [Full Text] [Related]
9. Gastric carcinoid tumors as a consequence of chronic hypergastrinemia: spiral CT findings.
Ho AC; Horton KM; Fishman EK
Clin Imaging; 2000; 24(4):200-3. PubMed ID: 11274882
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with elevated serum chromogranin A levels in patients with autoimmune gastritis.
Kalkan Ç; Karakaya F; Soykan İ
Turk J Gastroenterol; 2016 Nov; 27(6):515-520. PubMed ID: 27852542
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study.
Thomas D; Tsolakis AV; Grozinsky-Glasberg S; Fraenkel M; Alexandraki K; Sougioultzis S; Gross DJ; Kaltsas G
Eur J Endocrinol; 2013 Feb; 168(2):185-93. PubMed ID: 23132699
[TBL] [Abstract][Full Text] [Related]
12. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
Campana D; Nori F; Pezzilli R; Piscitelli L; Santini D; Brocchi E; Corinaldesi R; Tomassetti P
Endocr Relat Cancer; 2008 Mar; 15(1):337-42. PubMed ID: 18310299
[TBL] [Abstract][Full Text] [Related]
13. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
Khuroo MS; Khuroo MS; Khuroo NS
J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
[TBL] [Abstract][Full Text] [Related]
14. [Primary and follow-up studies of patients with carcinoid metastases using indium 111 octreotide--rational use of Sandostatin].
Lipp RW; Hammer HF; Passath A; Dobnig H; Ramschak-Schwarzer S; Stiegler C; Leb G; Krejs GJ
Acta Med Austriaca; 1993; 20(1-2):42-4. PubMed ID: 8475679
[TBL] [Abstract][Full Text] [Related]
15. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide.
Imtiaz KE; Monteith P; Khaleeli A
Clin Endocrinol (Oxf); 2000 Dec; 53(6):755-8. PubMed ID: 11155099
[TBL] [Abstract][Full Text] [Related]
16. [Treatment with octreotide (SMS 201-995) in a case of intestinal carcinoid tumor].
Goñi F; Oleaga A; Goñi MJ; Monreal M; Yoldi A; González A; Llorente I; Moncada E
Rev Clin Esp; 1991 Nov; 189(7):331-4. PubMed ID: 1722585
[TBL] [Abstract][Full Text] [Related]
17. Treatment of ECL cell carcinoids with octreotide LAR.
Fykse V; Sandvik AK; Qvigstad G; Falkmer SE; Syversen U; Waldum HL
Scand J Gastroenterol; 2004 Jul; 39(7):621-8. PubMed ID: 15370681
[TBL] [Abstract][Full Text] [Related]
18. Carcinoid tumor regression with high-dose octreotide acetate: a patient report.
Lokich J
Am J Clin Oncol; 1998 Jun; 21(3):246-7. PubMed ID: 9626790
[TBL] [Abstract][Full Text] [Related]
19. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature.
Leong WL; Pasieka JL
J Surg Oncol; 2002 Mar; 79(3):180-7. PubMed ID: 11870669
[TBL] [Abstract][Full Text] [Related]
20. [Analogs of somatostatin and carcinoid tumors].
Gutiérrez Rodero F; Morales Cano JM; de Blas Laborda C; González Barber A
Med Clin (Barc); 1990 Jun; 95(2):78-9. PubMed ID: 2250512
[No Abstract] [Full Text] [Related]
[Next] [New Search]
